Welcome to our dedicated page for 60 Degrees Pharm news (Ticker: SXTPW), a resource for investors and traders seeking the latest updates and insights on 60 Degrees Pharm stock.
60 Degrees Pharmaceuticals Inc. (SXTPW) is a clinical-stage company developing innovative therapies for infectious diseases, notably malaria prophylaxis through its FDA-approved product ARAKODA. This page serves as the definitive source for official company announcements, research milestones, and regulatory developments.
Investors and healthcare professionals will find timely updates on clinical trials, partnership agreements, and therapeutic advancements. Our curated collection includes press releases covering drug development progress, peer-reviewed research findings, and strategic initiatives in tropical medicine.
Key content areas include malaria prevention updates, babesiosis treatment research, FDA regulatory communications, and collaborative studies with academic institutions. All materials are sourced directly from company filings and verified channels to ensure reliability.
Bookmark this page for streamlined access to SXTPW's latest developments in infectious disease therapeutics. Check regularly for updates on pipeline innovations and clinical trial data impacting global health outcomes.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has reported its Q1 2025 financial results, showing mixed performance. The company's net product revenues increased 55% year-over-year to $163.6 thousand, primarily driven by domestic sales of ARAKODA®. Gross profit saw significant growth of 124%, reaching $90.3 thousand compared to $40.2 thousand in Q1 2024.
However, operating expenses rose to $2.09 million from $1.41 million in the previous year, with $535.4 thousand attributed to increased sales, investor-related services, and stock-based compensation. The company reported a net loss of $2.01 million ($1.56 per share) in Q1 2025, compared to a net income of $308.7 thousand ($1.83 per share) in Q1 2024, largely due to a $1.74 million change in fair value of derivative liabilities.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) reveals groundbreaking survey results suggesting babesiosis disease burden in the US is significantly higher than CDC estimates. The survey, conducted among 6,000 US adults, found that 1.26% of respondents (equivalent to ~3 million people) reported receiving a babesiosis diagnosis in their lifetime, compared to CDC's 1,834 reported cases in 2020.
The study indicates that approximately 17% of babesiosis patients experienced illness lasting six months or more, suggesting around 570,000 US adults have faced chronic disease. Additionally, 3.7% of respondents (~9.9 million Americans) reported experiencing chronic fatigue lasting longer than six months, with 56% of these individuals having received a formal Chronic Fatigue Syndrome diagnosis.
This significant disparity between survey findings and CDC statistics suggests babesiosis may be substantially underdiagnosed or underreported, potentially indicating a larger market for effective treatments.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) CEO Geoff Dow will participate in the Healing Lyme Summit from April 15-21, 2025, to discuss babesiosis, a tick-borne disease commonly occurring alongside Lyme disease. Dr. Dow will address the increasing prevalence of babesiosis in the United States, clinical challenges, and the need for better diagnostic and treatment options.
The company is currently conducting two clinical trials (NCT06207370 and NCT06478641) evaluating tafenoquine for treating severe babesiosis and persistent disease in immunosuppressed patients. The summit is a free virtual event featuring scientific discussions and educational content on tick-borne illnesses.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has signed a Patent License Agreement with Yale School of Medicine and Yale School of Public Health to advance the development and commercialization of tafenoquine for babesiosis treatment and prevention.
The agreement follows collaborative research between the organizations studying tafenoquine's activity against babesiosis, a tick-borne disease that infects red blood cells. Currently, tafenoquine is not FDA-approved for babesiosis treatment and prevention.
If approved, tafenoquine could address a significant unmet medical need, particularly for patients who progress beyond initial mild symptoms. The drug could potentially become the first prophylaxis available for babesiosis. According to Dr. Peter James Krause from Yale, relapsing babesiosis in immunocompromised patients has an estimated mortality rate of 20 percent and is challenging to treat.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) reported significant financial growth for FY 2024. Net product revenues increased 140% to $607.6 thousand, driven by domestic sales of ARAKODA®. The company achieved a gross profit of $222.8 thousand in 2024, compared to a $221 thousand loss in 2023.
Operating expenses rose to $10.0 million in 2024 from $4.9 million in 2023, primarily due to non-recurring R&D charges and babesiosis clinical trial costs. Net loss widened to $8.43 million ($18.55 per share) from $3.925 million ($59.18 per share) in 2023.
Key developments include:
- FDA approval to import Kodatef® (Australian equivalent of Arakoda) due to increased U.S. demand
- Ongoing babesiosis clinical trials with interim analysis expected in Q1 2026
- Additional Arakoda supply lots scheduled for release in early Q2 2025
- Expansion of clinical studies for babesiosis treatment in various patient groups
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has announced a 1-for-5 reverse stock split of its common stock, effective February 24, 2025. The primary purpose is to comply with Nasdaq's $1.00 minimum bid price requirement to maintain listing. The stock will continue trading under 'SXTP' with a new CUSIP number 83006G401.
The reverse split will automatically convert every five current shares into one new share. Proportional adjustments will be made to outstanding equity awards, warrants, convertible notes, and shares under stock incentive plans. The split won't alter the par value, authorized share count, or stockholders' percentage ownership. No fractional shares will be issued; all will be rounded up to the next whole share.
Stockholders don't need to take action, as positions will be automatically adjusted. The company notes there's no guarantee it will meet the minimum bid requirement.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) announced FDA's non-objection to import KODATEF® (tafenoquine) from Australia as a one-time measure to prevent potential supply disruptions of ARAKODA® in the U.S. market. Both medications are identical antimalarial drugs for adults 18 and older, with ARAKODA being the U.S. brand name and KODATEF being the Australian version.
The company plans to import a five-month supply of KODATEF while increasing ARAKODA manufacturing capacity, responding to growing product demand and awareness in the U.S. This proactive measure aims to ensure continuous availability of tafenoquine for malaria prophylaxis to healthcare providers.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has closed a registered direct offering priced at-the-market, raising approximately $1.075 million in gross proceeds through the sale of 1,503,500 common stock shares at $0.715 per share. The company also issued unregistered short-term warrants in a concurrent private placement to purchase up to 1,503,500 shares at $0.59 per share, exercisable for 24 months.
This offering, combined with previous fundraising since early 2025, brings total gross proceeds to $2.118 million. The company plans to use the net proceeds for working capital and general corporate purposes. H.C. Wainwright & Co. served as the exclusive placement agent for the offering.
FAQ
What is the current stock price of 60 Degrees Pharm (SXTPW)?
